» Articles » PMID: 1702726

Induction of Tolerance in Peripheral T Cells with Monoclonal Antibodies

Overview
Journal Eur J Immunol
Date 1990 Dec 1
PMID 1702726
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

Our goal has been to develop ways to tolerize the mature immune system to any defined antigen. In this report we show that peripheral (post-thymic) T cells of mice can become tolerant to a range of antigens (human and rat immunoglobulins, and bone marrow and skin grafts that differ at multiple minor transplantation antigens). In the case of human gamma globulin (HGG), this required that the antigen be given under the cover of a short course of non-depleting anti-CD4 antibody, while for tolerance to skin and marrow grafts anti-CD8 antibody was also required. Tolerance to HGG could be reinforced by repeated injections of HGG, but was lost in the absence of any further exposure to antigen. This reversal of tolerance with time was due to new T cells being exported from the thymus, as it was not observed in tolerized, adult thymectomized mice. In contrast, tolerance to marrow and skin grafts was permanent, presumably because the established grafts acted as a continuous source of antigen to reinforce the tolerant state. Tolerance could not be broken by the infusion of unprimed spleen cells and in one example (tolerance to Mls-1a) there was clear evidence that specific peripheral T cells were anergic. We propose that anergic cells may themselves participate in reinforcing the tolerant state by competing at sites of antigen presentation.

Citing Articles

Structure, function, and immunomodulation of the CD8 co-receptor.

Srinivasan S, Zhu C, McShan A Front Immunol. 2024; 15:1412513.

PMID: 39253084 PMC: 11381289. DOI: 10.3389/fimmu.2024.1412513.


Universal CAR T cells targeted to HER2 with a biotin-trastuzumab soluble linker penetrate spheroids and large tumor xenografts that are inherently resistant to trastuzumab mediated ADCC.

Nagy L, Mezosi-Csaplar M, Rebenku I, Vereb G, Szoor A Front Immunol. 2024; 15:1365172.

PMID: 38562932 PMC: 10982377. DOI: 10.3389/fimmu.2024.1365172.


CTLA4-Ig Effectively Controls Clinical Deterioration and Immune Condition in a Murine Model of Foxp3 Deficiency.

Gerbaux M, Roos E, Willemsen M, Staels F, Neumann J, Bucken L J Clin Immunol. 2023; 43(6):1393-1402.

PMID: 37156988 PMC: 10354160. DOI: 10.1007/s10875-023-01462-2.


Cytolytic Activity of CAR T Cells and Maintenance of Their CD4+ Subset Is Critical for Optimal Antitumor Activity in Preclinical Solid Tumor Models.

Csaplar M, Szollosi J, Gottschalk S, Vereb G, Szoor A Cancers (Basel). 2021; 13(17).

PMID: 34503109 PMC: 8428348. DOI: 10.3390/cancers13174301.


Molecular Approaches for the Treatment of Pompe Disease.

Bellotti A, Andreoli L, Ronchi D, Bresolin N, Comi G, Corti S Mol Neurobiol. 2019; 57(2):1259-1280.

PMID: 31713816 DOI: 10.1007/s12035-019-01820-5.